Appili recognizes the importance of social media, including Twitter, and new communication channels that enable Appili to engage in interactive discussion with the Company’s stakeholders. As a clinical-stage drug development company, Appili is committed to abiding by the legal, ethical and regulatory standards applicable to the Company. By maintaining an active Twitter account, Appili aims to responsibly interact with stakeholders.
Appili may respond to questions and comments that are presented via Twitter when appropriate. Appili may not be able to respond immediately to questions or comments, and responses, if any, may be limited in nature.
There may be questions and/or comments that Appili cannot address, including, but not limited to, questions that are related to non-public confidential information, proprietary information, financial matters, ongoing legal matters, regulatory issues and other aspects of Appili’s business. Appili will not respond to rumors, personal attacks, foul language, disparaging comments or topics that do not relate directly to Appili.
Appili may provide links or references to external websites that are not controlled by Appili as part of its Tweets. However, Appili does not endorse or claim responsibility for the content of such websites. Any links or references to such external websites are provided merely as a convenience to the users of the Twitter platform.